| 產(chǎn)品編號(hào) | bs-6827R-FITC |
| 英文名稱 | Rabbit Anti-MAGEC2/FITC Conjugated antibody |
| 中文名稱 | FITC標(biāo)記的黑色素瘤相關(guān)抗原C2抗體 |
| 別 名 | Cancer testis antigen 10; Cancer/testis antigen 10; CT10; HCA587; Hepatocellular carcinoma associated antigen 587; Hepatocellular carcinoma-associated antigen 587; MAGC2_HUMAN; MAGE C2 antigen; MAGE E1 antigen; MAGE-C2 antigen; MAGE-E1 antigen; MAGEC2; Melanoma associated antigen C2; Melanoma-associated antigen C2; MGC13377. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買 大包裝/詢價(jià) |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 腫瘤 免疫學(xué) 腫瘤細(xì)胞生物標(biāo)志物 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human, Mouse, Rat, Pig, Cow, ) |
| 產(chǎn)品應(yīng)用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 41kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human MAGEE1/MAGEC2 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: Tissue specificity; Not expressed in normal tissues, except in germ cells in the seminiferous tubules and in Purkinje cells of the cerebellum. Expressed in various tumors, including melanoma, lymphoma, as well as pancreatic cancer, mammary gland cancer, non-small cell lung cancer and liver cancer. In hepatocellular carcinoma, there is a inverse correlation between tumor differentiation and protein expression, i.e. the lower the differentiation, the higher percentage of expression. Function: Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination in presence of Ubl-conjugating enzyme UBE2H leading to p53/TP53 degradation. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzymes (E2) at the E3:substrate complex. Subunit: Interacts with TRIM28 and UBE2H. Subcellular Location: Cytoplasm. Nucleus. Nuclear in germ cells. Cytoplasmic in well-differentiated hepatocellular carcinoma, nuclear in moderately- and poorly-differentiated hepatocellular carcinoma. Tissue Specificity: Expressed in various tumors, including melanoma, lymphoma, as well as pancreatic cancer, mammary gland cancer, non-small cell lung cancer and liver cancer. In hepatocellular carcinoma, there is a inverse correlation between tumor differentiation and protein expression, i.e. the lower the differentiation, the higher percentage of expression. Similarity: Contains 1 MAGE domain. Database links: UniProtKB/Swiss-Prot: Q9UBF1.1 Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
